Biogen, Roche Revise Deal - Zacks.com

Bizjournals.com

Biogen, Roche Revise Deal Zacks.com ... like Rituxan (rituximab) approved for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphoid leukemia (CLL), and rheumatoid arthritis (RA), ... Roche, Biogen end dispute over Rituxan follow-onsReuters Biogen, Genentech restructure MS drug agreementMass High Tech Biogen, Roche Alter Pact For Rituxan, Follow-Up DrugsWall Street Journal BioMedReports (subscription) -National Post (registration) -Genetic Engineering News all 49 news articles »

CORRECT: NICE Not Minded To OK Merck's Simponi, Wants More Data - Wall Street Journal

CORRECT: NICE Not Minded To OK Merck's Simponi, Wants More Data Wall Street Journal Also known as golimumab, Simponi is a follow-up drug to Remicade, which treats rheumatoid arthritis and gastrointestinal conditions and which had worldwide ... NHS needs more data on rheumatoid arthritis drugWebMD.Boots.com UK NICE Appraisal Consultation on Merck & Co's Simponi for rheumatoid ...The Pharma Letter (subscription) all 8 news articles »

EU prepares for biosimilar antibody drugs - Reuters

EU prepares for biosimilar antibody drugs Reuters Teva already has clinical studies under way comparing its copy of Roche's antibody drug Rituxan to the original in treating both rheumatoid arthritis and ... and more »

Ocrelizumab - Top 10 Phase III Failures - FierceBiotech

Ocrelizumab - Top 10 Phase III Failures FierceBiotech At the end of 2009, ocrelizumab looked every inch of a blockbuster for rheumatoid arthritis. The drug hit its primary endpoint in a Phase III, ... and more »